Wyeth discloses new CEO's salary

Wonder what a big cheese in Big Pharma earn these days? Well, Wyeth told the Securities & Exchange Commission that it plans to pay its new chief Bernard Poussot (photo) $1.5 million in base salary, plus 120,000 restricted stock units that start vesting in three years. Meanwhile, its non-employee directors will get $220,000 annually in 2008 and 2009.

Remember, though, that base pay is just that. According to Forbes, Wyeth's current CEO, Robert Essner, raked in $25.66 million in 2006, including base pay, bonuses, stock, and perks.

- read the AP report
- see the figures on Essner in Forbes

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.